X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs LUPIN LTD - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA LUPIN LTD SUN PHARMA/
LUPIN LTD
 
P/E (TTM) x 16.8 17.7 94.8% View Chart
P/BV x 3.4 4.1 82.0% View Chart
Dividend Yield % 0.7 0.7 91.0%  

Financials

 SUN PHARMA   LUPIN LTD
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
LUPIN LTD
Mar-16
SUN PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs8422,127 39.6%   
Low Rs5721,294 44.2%   
Sales per share (Unadj.) Rs131.6304.1 43.3%  
Earnings per share (Unadj.) Rs32.750.4 64.9%  
Cash flow per share (Unadj.) Rs38.060.7 62.6%  
Dividends per share (Unadj.) Rs3.507.50 46.7%  
Dividend yield (eoy) %0.50.4 112.9%  
Book value per share (Unadj.) Rs152.7243.8 62.6%  
Shares outstanding (eoy) m2,399.26450.58 532.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.45.6 95.5%   
Avg P/E ratio x21.633.9 63.7%  
P/CF ratio (eoy) x18.628.2 66.1%  
Price / Book Value ratio x4.67.0 66.0%  
Dividend payout %10.714.9 71.9%   
Avg Mkt Cap Rs m1,696,877770,740 220.2%   
No. of employees `00017.516.4 107.1%   
Total wages/salary Rs m49,02321,077 232.6%   
Avg. sales/employee Rs Th18,028.38,379.6 215.1%   
Avg. wages/employee Rs Th2,798.81,289.0 217.1%   
Avg. net profit/employee Rs Th4,479.51,388.7 322.6%   
INCOME DATA
Net Sales Rs m315,784137,016 230.5%  
Other income Rs m6,2321,877 332.0%   
Total revenues Rs m322,016138,893 231.8%   
Gross profit Rs m100,89337,535 268.8%  
Depreciation Rs m12,6484,635 272.9%   
Interest Rs m3,998446 896.0%   
Profit before tax Rs m90,47934,330 263.6%   
Minority Interest Rs m0-88 0.0%   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,11611,536 105.0%   
Profit after tax Rs m78,46222,707 345.5%  
Gross profit margin %31.927.4 116.6%  
Effective tax rate %13.433.6 39.9%   
Net profit margin %24.816.6 149.9%  
BALANCE SHEET DATA
Current assets Rs m329,53797,790 337.0%   
Current liabilities Rs m178,87053,872 332.0%   
Net working cap to sales %47.732.1 148.9%  
Current ratio x1.81.8 101.5%  
Inventory Days Days7985 93.3%  
Debtors Days Days83121 68.7%  
Net fixed assets Rs m204,76686,379 237.1%   
Share capital Rs m2,399901 266.2%   
"Free" reserves Rs m363,997105,735 344.3%   
Net worth Rs m366,397109,844 333.6%   
Long term debt Rs m14,36153,739 26.7%   
Total assets Rs m614,102224,378 273.7%  
Interest coverage x23.677.9 30.3%   
Debt to equity ratio x00.5 8.0%  
Sales to assets ratio x0.50.6 84.2%   
Return on assets %13.410.3 130.1%  
Return on equity %21.420.7 103.6%  
Return on capital %24.821.2 117.1%  
Exports to sales %049.1 0.0%   
Imports to sales %07.4 0.0%   
Exports (fob) Rs mNA67,244 0.0%   
Imports (cif) Rs mNA10,199 0.0%   
Fx inflow Rs m44,11871,405 61.8%   
Fx outflow Rs m24,48417,807 137.5%   
Net fx Rs m19,63453,598 36.6%   
CASH FLOW
From Operations Rs m70,822-3,690 -1,919.5%  
From Investments Rs m-42,216-69,434 60.8%  
From Financial Activity Rs m-22,85458,126 -39.3%  
Net Cashflow Rs m6,107-14,998 -40.7%  

Share Holding

Indian Promoters % 63.7 46.6 136.7%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 5.1 11.3 45.4%  
FIIs % 23.0 31.9 72.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.1 82.2%  
Shareholders   133,026 98,259 135.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Tata Stocks Rally(Closing)

Indian share markets continued to trade range bound in afternoon session with market participants awaiting the US Federal Reserve's policy statement this week.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Kim Jong Un Is Keeping Traders Busy(Daily Profit Hunter)

Sep 6, 2017

You shouldn't worry about North Kore, War or Market Corrections.

180,000%: The Returns That Could Have Been(The 5 Minute Wrapup)

Sep 7, 2017

For successful investing in small caps, it's important to know when not to press the panic button.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

Home Prices Chart a Steady Rise(Chart Of The Day)

Sep 7, 2017

Home prices data throws up a positive surprise.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 19, 2017 03:36 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS